



<b>Situation Report: Confirmed COVID-19</b>	<b>Location: The Gambia</b>
<b>Date of Report: 29<sup>th</sup> November – 2<sup>nd</sup> December 2021</b>	<b>Investigation Start Date: 17<sup>th</sup> March 2020 as of 18hrs.</b>
<b>Prepared by: Epidemiology and Disease Control Unit, MoH, The Gambia</b>	

## I. HIGHLIGHTS

This is the **404<sup>th</sup>** national situation report since the confirmation of the first case of the coronavirus disease (COVID-19) in The Gambia, on the **16<sup>th</sup> March 2020**

- **No** new COVID-19-related death registered, bringing the total to **342 (Crude Case-Fatality Ratio, 3.4%)**
- **Six (6)** new cases were registered (**Cumulative cases 9,998**)  
**One (1), two (2), one (1), and two (2)** cases were reported on the **29<sup>th</sup>, 30<sup>th</sup> November 2021** and **1<sup>st</sup> and 2<sup>nd</sup> December 2021** respectively
- The test positivity rate is **0.66% (6/910)**, **NPHL –861 (6 positives)** and **MRCG – 49 (0 Positives)**
  - **One (1) case** is currently on **oxygen therapy**
- Only **one (1)** case was discharged after at least **10** days from the day they tested positive but evaded institutional isolation and **zero (0)** from COVID-19 treatment centres
- As of **2<sup>nd</sup> December 2021**, the following number of people have been vaccinated with:
  - **Johnson & Johnson:**
    - **Only 1 dose:** 194,845
  - **Sinopharm:**
    - **Dose 1:** 4,468
    - **Dose 2:** 3,312
  - **AstraZeneca:**
    - **Dose 1:** 40,661
    - **Dose 2:** 27,880
- **TARGET POPULATION** (based on microplanning estimates - **1,564,214**)
  - Proportion of target population fully vaccinated (2 doses of AZ/Sinopharm OR 1 dose of J&J): **14.5%**
  - Proportion of target population that received at least one Covid-19 vaccine dose (AZ OR J&J OR Sinopharm): **15.3%**
- **TOTAL POPULATION** (Based on final MoH population projections for 2021 - **2,438,899**)
  - Proportion of total population fully vaccinated (2 doses of AZ/Sinopharm OR 1 dose of J&J): **9.3%**
  - Proportion of total population that received at least one Covid-19 vaccine dose (AZ OR J&J OR Sinopharm): **9.8%**

### COVID-19 SITUATION IN NUMBERS

#### Globally

- Confirmed Cases: **265,525,077**
- Recoveries: **239,253,881**
- Deaths: **5,262,759**


#### Senegal

- Confirmed Cases: **74,013**
- Recoveries: **72,101**
- Deaths: **1,886**

#### The Gambia


- Confirmed Cases: **9,998**
- Active Cases: **15**
- Recoveries: **9,641**
- Deaths: **342**

## II. EPIDEMIOLOGICAL DESCRIPTION



**Fig 1: Geographic Distribution of COVID-19 Cases per 100,000 Pop. by Region since the start of the Pandemic to 31<sup>st</sup> October (Number Above) and October only (Number below) in The Gambia**

- Western 1 Health Region has a disproportionately higher number of cases than all the health regions (**See Fig. 1**)
- Below are the age-sex distribution and the Epi-curve of confirmed cases by date of sample collection, respectively (**See Fig. 2 and 3**)




**Fig 2: Age-Sex Distribution of Confirmed COVID-19 Cases, The Gambia, 2021**

✧ This excludes the 27 confirmed cases whose demographic information are not yet available

About 59% of the confirmed cases are males (**See Fig. 2**)

About 59% of the confirmed cases are 40 years below (**See Fig. 2**)



**Fig. 3: Epidemic Curve of Laboratory-Confirmed Cases Reported daily, COVID-19 Pandemic, The Gambia, 16<sup>th</sup> March 2020-28<sup>th</sup> November 2021\*.**

A considerable amount of time elapsed between date of reporting and the date of laboratory confirmation of some cases

- Three main waves of infection occurred – the pre airport closure wave, the importation from Senegal wave and the intermittent airport re-opening and loosening of restrictions wave

**Table 1: Summary of New and Cumulative Public Health Response Outputs, COVID-19 Pandemic, The Gambia, 2021**

Status	New	Cumulative
No. of active cases in institutional isolation		1
No. of COVID-19 patients on oxygen support		1
No. of patients recovered and discharged	0	
In Hotel Quarantine	0	19
Completed Hotel Quarantine	0	5,240
Completed follow-up (asymptomatic people with travel history to affected countries) *	0	310
No. of Contact(s) Identified**	0	
No. of Contacts being monitored	0	
No. of Contacts who completed 14-day follow-up	0	17,119
No. of Contacts lost to follow-up	0	58
Total Tests conducted (Repeat Tests)***	910(0)	125,971
Positive test result (Repeat Tests)***	6(0)	9,998
Negative test result (Repeat Tests)***	904(0)	114,716
Inconclusive test result (Repeat Tests)***	0(0)	

\* Follow-up completed prior to the 17<sup>th</sup> March (when the first confirmed case was reported)

\*\* Includes both low-risk and high-risk contacts and not mutually exclusive with number quarantined (as some have been quarantined)

\*\*\* Includes repeat tests in bracket

Region	<29/11/2021	29/11/2021	30/11/2021	01/12/2021	02/12/2021	Total
CRR	36252	0	107	0	0	36,359
LRR	17977	0	0	0	0	17,977
NBER	14985	20	0	0	104	15,109
NBWR	18656	0	62	0	0	18,718
URR	38421	153	274	0	336	39,184
WR1	105549	74	108	305	128	106,164
WR2	37091	0	0	400	164	37,655
<b>Total</b>	<b>268,931</b>	<b>247</b>	<b>551</b>	<b>705</b>	<b>732</b>	<b>271,166</b>

Table 2: Summary by region (Total doses administered from the beginning of COVID-19 vaccination in The Gambia)

Table 3: Major response activities undertaken newly, COVID-19 Outbreak, The Gambia, 2021

### III. MAJOR RESPONSE ACTIVITIES

Component	Interventions
Coordination	<ul style="list-style-type: none"> <li>Coordination meetings held at both central and regional levels</li> </ul>
Surveillance/ Laboratory	<ul style="list-style-type: none"> <li>A total of <b>910</b> new laboratory test results received <b>861</b> from <b>NPHL</b> and <b>49</b> from <b>MRCG</b> <ul style="list-style-type: none"> <li>Of these, <b>no</b> test result returned inconclusive or indeterminate, <b>6</b> new samples tested positive</li> </ul> </li> </ul>
Case Management / Psychosocial Support & Research / IPC	<ul style="list-style-type: none"> <li><b>No</b> new COVID-19 related death recorded</li> <li><b>No</b> patient was newly discharged from treatment centres</li> <li><b>No</b> new contacts traced and monitored</li> <li><b>One</b> (1) COVID-19 patient is currently on <b>oxygen therapy</b></li> </ul>

#### **IV. GAPS/CHALLENGES:**

- CBS activities not replicated in all regions to increase the number of daily tests being conducted
- Support for innovative countrywide risk communication strategies and activities on COVID-19 is suboptimal
- Dwindling compliance with mask-wearing requirements
- Low turn-out at COVID-19 sample collection sites resulting in fewer number of daily tests
- Denial, misinformation, stigma and discrimination against COVID-19 affected families.
- Low COVID-19 vaccination coverage rate

#### **V. NEXT STEPS/RECOMMENDATIONS:**

- CBS activities need to be synchronized with MRC's ILI surveillance to spur up testing rates in the hinterland.
- Strengthen community-based surveillance in all regions to increase awareness and testing rates
- Intensify risk communication and community engagement activities, on COVID-19 at community level, including at LUMOS, in a bid to curtail community transmission and dispel misinformation and denial and vaccine hesitancy
- Thorough enforcement of the mandatory mask-wearing regulation
- IPC measures should be strictly adhered to in all public and private health healthcare facilities
- Provision of adequate stocks of PPEs to all health facilities
- Health workers to observe all COVID-19 preventive measures always including the donning of appropriate PPEs
- Intensify activities geared to increased COVID-19 vaccination coverage at all levels

**For comments or questions, please contact:**  
**Sana M. Sambou**  
Public Health Emergency Operations Center  
Epidemiology and Disease Control Unit, The Gambia  
Email: [sanamsambou@hotmail.com](mailto:sanamsambou@hotmail.com) Phone: +220 3516320/2422949/3921415

**PARTNERS**

